EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections

D Fresan, S Luque, A Benítez-Cano, L Sorlí, M Milagro Montero, M De-Antonio, N Prim, V Vega, J P Horcajada, S Grau

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkac439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von D Fresan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Ceftazidime, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Therapeutic drug monitoring (TDM) of β-lactams in critically ill patients has been correlated with better clinical outcomes. Evidence on TDM of newer β-lactams such as ceftazidime/avibactam administered by continuous infusion (CI) is very limited.

Objectives

To describe our experience with TDM of ceftazidime/avibactam and pharmacokinetic/pharmacodynamic (PK/PD) target attainment in patients with MDR bacterial infections. Clinical outcomes of ceftazidime/avibactam administered by CI were also assessed.

Methods

Patients treated with ceftazidime/avibactam administered by CI and undergoing TDM of ceftazidime plasma concentrations were included. Blood samples were obtained as part of the TDM program. The PK/PD therapeutic target of ceftazidime/avibactam was defined as 100%fT > 4 × MIC of the causative pathogen, and 100%fT > 10 × MIC was considered overexposure. Dose changes were made according to the TDM results.

Results

Thirty-one patients were included. Ceftazidime/avibactam total daily doses ranged from 1 g/0.25 g to 6 g/1.5 g. Twenty-six patients (83.9%) achieved a 100%fT > 4 × MIC, 15 (48.4%) of which were overexposed (100%fT > 10 × MIC). Dose reduction was suggested in 16/28 (57.1%) patients and dose maintenance in 12/28 (42.9%). Overall clinical cure was observed in 21 (67.7%) patients, and 18 of these (85.7%) achieved a 100%fT > 4 × MIC.

Conclusions

Administering ceftazidime/avibactam by CI enabled the desired PK/PD target to be achieved in a large proportion of patients, even at lower doses than those recommended for a 2 h extended infusion. We suggest that the use of CI with TDM may be a useful tool for reducing initial doses, which could help to reduce antimicrobial-related adverse effects and treatment costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeGram-Negative Bacterial InfectionsHumansAnti-Bacterial AgentsDrug MonitoringAzabicyclo CompoundsDrug CombinationsMicrobial Sensitivity Tests

Substanzen

CeftazidimeAnti-Bacterial AgentsavibactamAzabicyclo CompoundsDrug Combinations

Autor:innen und Institutionen

  • Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Spain.
  • Pharmacy Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain.
  • Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.
  • CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Av. de Monforte de Lemos, 5, Madrid 28029, Spain.
  • Department of Anaesthesiology and Surgical Intensive Care, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain.
  • Infectious Diseases Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain.

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Fresan, D., Luque, S., Benítez-Cano, A., Sorlí, L., Milagro Montero, M., De-Antonio, M., Prim, N., Vega, V., Horcajada, J. P., & Grau, S. (2023). Pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkac439

Vancouver

Fresan D, Luque S, Benítez-Cano A, Sorlí L, Milagro Montero M, De-Antonio M, et al. Pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkac439

BibTeX
@article{Fresan2023,
  author = {Fresan, D and Luque, S and Benítez-Cano, A and Sorlí, L and Milagro Montero, M and De-Antonio, M and Prim, N and Vega, V and Horcajada, J P and Grau, S},
  title = {Pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkac439}
}
Kostenlos starten →